RA Capital targets China with latest SPAC deal

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. RA Capital Management has formed a new blank-check entity that it aims to take public and merge with a biotechnology or healthcare company in China. In a securities filing on Tuesday, the prominent venture capital firm outlined plans for its “Research Alliance III” to seek out a “target company” in China — the source of a large and growing number of drug licens ...